The effects of lumbar intrathecal (i.t.) and intracerebroventricular (i.c.v.) midazolam on nociception during iso¯urane anaesthesia were studied in rats using the tail-¯ick test. Rats received i.t. midazolam 2 and 4 mg or i.c.v. midazolam 4 and 8 mg during 1.1, 1.2 and 1.3% iso¯urane or without iso¯urane. Neither i.t. nor i.c.v. midazolam alone at doses studied in¯uenced nociceptive responses. 1.1% iso¯urane showed a minimum antinociceptive effect which was not in¯uenced by i.t. or i.c.v. midazolam. 1.2 and 1.3% iso¯urane produced moderate antinociception which was markedly potentiated by both i.t. and i.c.v. midazolam. The effects of midazolam shown in the present study are different from the reported effects of midazolam on opioidinduced antinociception; where spinally administered midazolam potentiates and supraspinal midazolam inhibits the antinociceptive effects of morphine. The present results suggest that midazolam potentiates iso¯urane-induced antinociception at doses where no effect is seen alone.
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Midazolam is commonly used as an adjunct to general anaesthesia and has been shown to decrease the anaesthetic requirements of volatile agents after i.v. administration in both animals 1 and humans. 2 3 However, in respect of a nociceptive action, both hyperalgesic 4 5 and antinociceptive 6 effects of systemically administered midazolam have been reported. Different results may be ascribed to the action of midazolam on the spinal cord and/or brain. Regionally administered midazolam within the central nervous system has been reported to produce different effects on nociception. Lumbar intrathecal (i.t.) administration of midazolam produces antinociception, 4 7 8 while intracerebroventricular (i.c.v.) injection produces a hyperalgesic response. 5 In combination with opioids, the effects of midazolam on nociception are also different depending on the route of administration; where i.t. injection potentiates the antinociceptive effects of morphine and i.c.v. injection inhibits opioid-induced antinociception.
9±11
These modulating effects of midazolam on opioid-induced antinociception have been suggested to be mediated at least partially through gamma-aminobutyric acid A (GABA A ) receptors. 9 10 12 With respect to the interaction of i.t. midazolam with inhalation anaesthetics, there has been one report 13 which showed that i.t. midazolam decreased iso¯urane minimum alveolar concentration (MAC) in rats. No study has examined whether a difference exists between the spinal and supraspinal actions of midazolam on antinociception induced by a volatile anaesthetic as observed in narcotic-induced antinociception. The current study therefore examined the in¯uence of i.t. or i.c.v. midazolam on nociception in rats anaesthetized with various concentrations of iso¯urane.
Materials and methods
This study was approved by the Committee of Ethics on Animal Experiments at the Yamaguchi University School of Medicine.
Male Wistar rats weighing 250±300 g (60±70 days after birth) were used. The animals were housed in a cage at 21±25°C under diurnal light condition and allowed free access to food and water prior to the experiment.
For implantation of an i.t. catheter, rats were anaesthetized with halothane, and a PE-10 catheter was aseptically inserted through the atlanto-occipital membrane into the intrathecal space. The catheter was advanced 8 cm caudally to position its tip at the level of lumbar enlargement of the spinal cord and secured to the subcutaneous tissue.
For implantation of an i.c.v. cannula, rats were anaesthetized by intraperitoneal administration of pentobarbital (50 mg kg ±1 ) and a 24-G stainless steel cannula was stereotaxically inserted into the right lateral ventricle under aseptic conditions according to the atlas of Paxinos and Watson (1986) (0.8 mm posterior from bregma, 1.5 mm lateral from the midline and 3.5 mm depth from the skull). The cannula was ®xed to the skull bones with methyl methacrylate cement.
A minimum period of 48 h elapsed between catheter implantation and the following experiment which was performed in animals with no neurobehavioural abnormality.
All catheters' positions were veri®ed at the end of experiment; i.t. catheter-implanted rats were given i.t. injection of 10 ml of 2% lidocaine and all showed bilateral paralysis hindlimbs. In addition, for postmortem con®rm-ation, i.t. catheter position and i.c.v. cannula, and for the assessment of the spread of solution, 10 ml and 5 ml of Evans Blue was injected i.t. and i.c.v., respectively.
Rats implanted with either i.t. catheter or i.c.v. cannula were assigned into four groups; Group I (n=24) received no inhalation of iso¯urane, Groups II, III and IV (n=30 in each) received iso¯urane 1.1%, 1.2% and 1.3%, respectively. Group I was further divided into four midazolam-treated groups (n=6 in each), each of which received 2 mg i.t. Midazolam (F. Hoffmann-La Roche, Swiss) was dissolved in 0.9% saline, so that desired dose was contained in 10 ml for i.t. injection or 5 ml for i.c.v. injection. In control groups at each iso¯urane concentration, rats received 10 ml of i.t. saline or 5 ml of i.c.v. saline. The i.t. and i.c.v. injections were made using a microsyringe over a period of 5 min and 10 min, respectively.
The doses of midazolam and concentrations of iso¯urane were selected on the basis of our preliminary results and of reported information.
11±13 Preliminarily, using rats with femoral artery catheterization, we found that Pa CO 2 and mean arterial pressure respectively were maintained at 4.7±6.0 kPa and above 70 mm Hg for more than 120 min under spontaneous respiration at 1.3% iso¯urane alone or with i.c.v. administration of 8 mg midazolam. Rats given midazolam 4 mg i.t. or 8 mg i.c.v. behaved normally. When the iso¯urane concentration was increased to 1.4%, tail-¯ick latencies were prolonged to greater than 15 s and severe respiratory depression or sometimes death ensued.
Before administration of midazolam or iso¯urane, an awake value of tail-¯ick latency (Analgesia meter, MK-330, Muromachi Kikai, Tokyo) was measured in each rat. The tail of each rat was placed on a focused projector lamp so that the beam was focused on the proximal third of the tail. The end-point of the test was represented by the number of seconds until the rat removed its tail from the beam. Beam intensity was regulated so that pre-anaesthetic awake latencies were 4±5 s. The cut-off time was set at 15 s.
Rats of Group I were minimally restrained in a specially designed plastic box¯ushed continuously with total 2 litres min ±1 of nitrogen and oxygen (FI O 2 =0.25). In the other groups, anaesthesia was induced with 3% iso¯urane in the same gas mixture as Group I (FI O 2 =0.25) and, thereafter, maintained with preselected anaesthetic concentrations (1.1%, 1.2% and 1.3%) under spontaneous respiration until the end of experiment. The concentrations of inhalational iso¯urane and oxygen were monitored continuously with a Datex Capnomac Anesthetic monitor (Helsinki, Finland). Rectal and skin temperature of the tail base were measured by a digital thermometer (6510 TC, Mallinckrodt Medical Inc., Ireland). Application of thermister probe neither disturbed spontaneous movement of the tail nor in¯uenced tail-¯ick latencies. Rectal and tail temperatures were maintained by means of external heating at 36.8±37.2°C and 36.2±36.4°C, respectively.
After a 30-min stabilization period at each concentration of iso¯urane (Groups II±IV), baseline tail-¯ick latencies were measured, and then midazolam or saline was administered i.t. or i.c.v. In order to avoid repeated stimulation without anaesthesia, the baseline measurement was omitted in Group I, and midazolam was administered i.t. or i.c.v. after a 30-min stabilization.
Measurement of tail-¯ick latencies were repeated at 10, 15, 20, 30, 45, 60, 90 and 120 min after the administration of midazolam or saline.
The antinociceptive effects of iso¯urane and midazolam were expressed as percentage of the maximum possible effect (% MPE) as follows: % MPE=(postdrug value ± awake value)/(cut-off time ± awake value)Q100.
Analysis of variance for repeated measures was used to evaluate the time-course effect of treatments. To compare % MPE and maximum antinociceptive effect (peak % MPE) among groups, factorial analysis of variance was used. Multiple comparisons were performed using Fisher's protected least signi®cant difference test. P<0.05 was considered statistically signi®cant.
Results
In Group I (iso¯urane 0%), i.t. or i.c.v. midazolam alone studied did not signi®cantly change % MPE over the 120-min observation period.
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In the control group at each concentration of iso¯urane (Groups II, III and IV), there were no differences in % MPE between i.t. and i.c.v. saline administration and therefore the data of i.t. and i.c.v. saline at each iso¯urane concentration were combined and served as control.
In Group II, mean % MPE of the control group was signi®cantly but minimally increased to 6±10% during 1.1% iso¯urane when compared with the awake value. Neither i.t. nor i.c.v. midazolam caused further changes in % MPE following administration.
The time courses of % MPE after administration of i.t. and i.c.v. midazolam in Groups III and IV respectively are shown in Figures 1 and 2 . In Groups III and IV, mean % MPE of the control group was signi®cantly increased to 31±38% during 1.2% iso¯urane and to 45±51% during 1.3% iso¯urane when compared with awake values. Both i.t. and i.c.v. midazolam at all doses caused a further increase in % MPE (Figs 1, 2) . At each anaesthetic concentration, there were no signi®cant differences in % MPE between midazolam given either i.t. or i.c.v. Table 1 shows peak % MPE (maximum % MPE during the measurement period in each rat) in each group. In Group I (iso¯urane 0%), there were no differences in peak % MPE between the subgroups given i.t. or i.c.v. midazolam. In Group II (1.1% iso¯urane), there were no signi®cant differences in peak % MPE between control and any treatment groups given midazolam. In Groups III and IV (1.2 and 1.3% iso¯urane), there were signi®cant differences in peak % MPE between respective control and all treatment groups with no inter-treatment group differences. Peak % MPEs in control and all treatment subgroups in Groups III and IV are signi®cantly higher than those in the corresponding subgroups of Groups I and II. There were no differences in peak % MPE in any subgroup between Groups III and IV, and no difference between Groups I and II.
Postmortem examination revealed that Evans Blue injected through the i.t. catheter and i.c.v. cannula spread 
Discussion
In the present study, iso¯urane 1.1±1.3% showed antinociceptive effects in a dose-related fashion, and both spinal and supraspinal administration of midazolam at doses not affecting nociceptive responses alone potentiated the antinociception produced by iso¯urane 1.2 and 1.3%. These results are in contrast to the reported effects of midazolam on opioid-induced antinociception which depend on the route of administration of midazolam (i.e., i.t. injection of midazolam potentiates opioid-induced analgesia, while i.c.v. injection inhibits).
9±11
Anatomical localization of the spinally or supraspinally administered agents in addition to their effects on motor function deserve comment. We con®rmed that the distribution of Evans Blue injected i.t. (10 ml) and i.c.v. (5 ml), was con®ned in the spinal and supraspinal localization, respectively. Thus, either effect of i.c.v. and i.t. drug is assumed independent, and not resulted from distribution to the remote subarachnoid space. As for the motor function, we did not observe any disturbance induced by midazolam at doses studied. Our i.t. doses of midazolam are far less than the minimum dose (40 mg) of i.t. midazolam required to produce catalepsy. 11 Midazolam 8 mg i.c.v. has been shown to cause catalepsy in rats. 11 However, in the present study, no animals exhibited catalepsy, and thus the observed results have not been in¯uenced by motor disturbance.
Several studies have demonstrated that intravenous midazolam decreased the requirement for volatile anaesthetic agents. 1±3 However, little is known about the exact site or mechanism of action. There has been only one report to our knowledge investigating the interaction of i.t. midazolam with inhalation anaesthetics with respect to nociception or anaesthetic potency. 13 Schwieger and coworkers 13 reported in rats that i. 20 have shown that suppression of pinch-evoked movement by halothane is antagonized by i.t. injection of bicuculline and picrotoxin at doses that have no in¯uence on the response latency when given alone, suggesting that halothane exerts its antinocifensive action through a GABA A receptor-related mechanism within the spinal cord.
The potentiating effect of i.t. midazolam on antinociception induced by iso¯urane in the current study is likely to be mediated by enhancement of the action of GABA on GABA A receptor in the spinal cord. Furthermore, antinociceptive effects of i.t. midazolam is suggested to be mediated via mechanisms related to opioid receptors. 7 15 21 Goodchild and co-workers 8 have strongly suggested that i.t. midazolam causes antinociception by a mechanism involving the delta opioid receptor. This possibility, though not examined in the present study, may be in part responsible for the observed potentiation.
In contrast to the observation that opioid-induced antinociception was antagonized by i.c.v. midazolam, i.c.v. injection of midazolam potentiated iso¯urane-induced antinociception in the present study. The potentiating effects of iso¯urane-induced antinociception by i.c.v. midazolam might be attributable to anaesthetic ef®cacy in contrast to analgesic effects of midazolam. However, such speculation cannot readily explain the current results. I.c.v. midazolam, given with 1.1% iso¯urane, produced no potentiation, while the effect of 1.2 and 1.3% iso¯urane (baseline % MPE: 35±50%) were increased by i.c.v. midazolam (% MPE to 90±100%). Although the possibility that an undetectable anaesthetic ef®cacy of midazolam may have contributed to increase the antinociceptive effects induced by iso¯urane 1.2 and 1.3% cannot be entirely excluded, the fact that there was no modulatory effect of the Anaesthetic potency of an agent does not necessarily correlate with analgesic action. Deady and co-workers 22 found that the ratio of anaesthetic potency measured by MAC or concentration inhibiting righting re¯ex versus analgesic potency measured by tail-¯ick latency was different among volatile anaesthetics. Niv and co-workers 4 also reported in rats that intraperitoneal injection of 10 mg kg ±1 of midazolam produced complete abolition of spontaneous movement but decreased tail-¯ick latencies compared with the awake values, suggesting a dissociation between anaesthetic depth and analgesic actions.
With respect to i.c.v. administration of midazolam alone, our results are consistent with a previous report which observed only minor in¯uence, if any, on nociceptive responses. 11 In addition to enhancement of the binding of GABA to GABA A receptors, midazolam has been reported to inhibit GABA metabolism in brain synaptosomes, suggesting GABA concentrations may be increased at the synapse. 23 Volatile anaesthetics also have modulatory actions on the function of GABA A -mediated inhibitory systems in the brain. This modulation seems to contribute to anaesthetic and possibly analgesic action, though the modulatory effects of anaesthetics are not simple. Banks and Pearce 24 reported that volatile anaesthetics produced both reduction of the peak amplitude and prolongation of the duration of miniature inhibitory postsynaptic currents in hippocampal neurons of brain slices, and concluded that net action is via enhanced inhibition. Moreover, in an in vitro study it was suggested that iso¯urane also increases GABA levels in the synaptic cleft and thus may enhance synaptic inhibition. 25 When used in conjuction with opioids, i.c.v. injection of midazolam has been shown to inhibit the antinociceptive effects of opioids through a mechanism related with GABA A receptor. 9 10 12 In addition, Rady and Fujimoto 9 have demonstrated an elimination of the effect of i.c.v. midazolam by i.t. pretreatment with dynorphin antiserum, indicating that the inhibitory effect of i.c.v. midazolam on opioid antinociception is mediated by the release of dynorphin A (1±17) in the spinal cord. Dynorphin A (1±17) is a putative endogenous kappa selective opioid and is reported to be a mediator of antianalgesic descending system in the spinal cord. 26 To our knowledge, the effects of volatile anaesthetics on antianalgesic descending systems have not been investigated. It has been reported that iso¯urane dose-dependently blocks spinal cord potentials evoked by a feedback loop through supraspinal structures, 27 though the relationship relevance to our data is unclear. When considering the effects of volatile anaesthetics on opioid receptor subtypes, various results have been reported. Campbell, Rowbotham and Lambert 28 reported that clinical concentrations of halothane had little effect on mu and delta opioid receptor binding, whereas in another study halothane inhibited both mu and kappa receptor binding. 29 These modulating effects of volatile anaesthetics and midazolam on GABA A and/or opioid receptors in the brain may contribute the potentiating effects of i.c.v. midazolam on iso¯urane-induced antinociception in the current study, though the precise mechanism remains to be elucidated.
In summary, both spinal and supraspinal midazolam at doses with no antinociceptive effects alone, potentiated iso¯urane-induced antinociception. These results are different from the effects of midazolam on opioid-induced antinociception, which is potentiated by spinal administration but inhibited by supraspinal injection of midazolam. The present study suggests that low doses of midazolam may enhance the antinociceptive effects of iso¯urane.
